MorphoSys AG

MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.
  • TickerMOR
  • ISINDE0006632003
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany
Thomas J. Schiessle

CFO Jens Hollstein geht per 31.12.20 vorzeitig

Das überraschende und vorzeitige Ausscheiden des langjährigen CFO Jens Hollstein per 31.12.20 verunsichert. Ab sofort wird ein Nachfolger gesucht. Der Cashbestand stieg nach Zahlungseingang von Incyte auf € 1.062 Mio. und eröffnet Opportunitäten. Die Pipeline umfasst 115 (Vj. 119) Projekte. COVID-19 war bis dato „kein Thema“.

Thomas J. Schiessle

CFO Jens Hollstein geht per 31.12.20 vorzeitig

Das überraschende und vorzeitige Ausscheiden des langjährigen CFO Jens Hollstein per 31.12.20 verunsichert. Ab sofort wird ein Nachfolger gesucht. Der Cashbestand stieg nach Zahlungseingang von Incyte auf € 1.062 Mio. und eröffnet Opportunitäten. Die Pipeline umfasst 115 (Vj. 119) Projekte. COVID-19 war bis dato „kein Thema“.

Victor Floc’h

MORPHOSYS: Feedbacks from Monjuvi’s expert event | BUY | EUR133

MORPHOSYS - BUY | EUR133(+23%) Feedbacks from Monjuvi’s expert event Monjuvi’s commercial rollout is well underway First line DLBCL is Monjuvi’s next big opportunity Expansion into other haematological malignancies

Thomas J. Schiessle

„Tafa“(Monjuvi®) Launch in den USA beschleunigt - Cash

Der EQUI.TS-Projektwert steigt nach der schnellen Aufnahme von Monjuvi® in 08/20 in die US-Behandlungsrichtlinien (prominente 2A-Kennzeichnung in der US-NCCN) für die Zweitlinien-Kombi-Behandlung bei R/R DLBCL. Erste Umsätze in 2020 werden u.E. möglich. Damit wird die nun bestätige Guidance 2020 u.E. „konservativ“.

Jean-Jacques Le Fur

MORPHOSYS: Tafasitamab (now Monjuvi) approved one month ahead of the PDUFA date | BUY | EUR130 vs. EUR135 (+20%)

MORPHOSYS - BUY | EUR130 vs. EUR135 (+20%) Tafasitamab (now Monjuvi) approved one month ahead of the PDUFA date Clearing up one of investors’ main concerns Key positioning vs CAR-Ts makes perfect sense in this context Buy reiterated supported by a EUR130 FV

Victor Floc’h

MORPHOSYS - BUY | EUR135 vs. EUR140 (+92%) Even if uncertainty remains, current valuation makes it de facto a BUY

Any Tafa’s sale in 2020 would be an upside No uncertainty can justify current valuation BUY reiterated and slight review of our FV

Expert Corporate Governance Service (ECGS)

MorphoSys – AGM 27 May 2020

General: The AGM is to be held in the form of a virtual AGM in accordance with the German Law to Mitigate the Consequences of the COVID-19 Pandemic. The physical presence of shareholders or their authorised proxies is not possible. The voting rights may therefore be exercised solely by postal vote or by granting authority to the proxies designated by the Company.   MorphoSys is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leadi...

Expert Corporate Governance Service (ECGS)

MorphoSys - AGM 22 May 2019

General: MorphoSys is one of the world’s leading biotechnology companies focusing on fully human antibodies. It's Partnered Discovery segment business applies the Company's proprietary technologies to the research, development and optimisation of therapeutic antibody drug candidates in partnerschips with pharmaceutical and biotechnology companies. In the second segment, Proprietary Development, MorphoSys develops innovative proprietary antibody products. MorphoSys's scientists concentrate on indications such as inflammatory and autoimmune diseases, as well as cancer and infectious diseases. A...

MORPHOSYS sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of MORPHOSYS (DE), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date September 18, 2020, the closing price was EUR 116.95 and its potential was estimated at EUR 135.48.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch